pH-activated and Enzyme-activated drug delivery systemSakshiSharma250807
As per the syllabus of M.Pharma (1st sem.) I have presented the topic pH-activated and Enzyme-activated. This comes under rate-controlled drug delivery system under the subject Drug delivery system. Best wishes from Sakshi Sharma
SUSTAINED RELEASE (SR) & CONTROL RELEASE.pptxRAHUL PAL
Sustained-release medications are usually labeled with “SR” at the end of their name. These medications prolong the medication's release from a tablet or capsule so that you'll get the medication's benefits over a longer period of time.
CR = controlled release, SR = sustained release, ER = extended release, IR = immediate release. *
Description about a type of activation modulated drug delivery system, which a type of control drug delivery system.
Also, give a detailed description about each subclassification.
CrDDS is one which delivers the drug at a predetermined rate, for locally or systematically, for a prolong period of time.
pH-activated and Enzyme-activated drug delivery systemSakshiSharma250807
As per the syllabus of M.Pharma (1st sem.) I have presented the topic pH-activated and Enzyme-activated. This comes under rate-controlled drug delivery system under the subject Drug delivery system. Best wishes from Sakshi Sharma
SUSTAINED RELEASE (SR) & CONTROL RELEASE.pptxRAHUL PAL
Sustained-release medications are usually labeled with “SR” at the end of their name. These medications prolong the medication's release from a tablet or capsule so that you'll get the medication's benefits over a longer period of time.
CR = controlled release, SR = sustained release, ER = extended release, IR = immediate release. *
Description about a type of activation modulated drug delivery system, which a type of control drug delivery system.
Also, give a detailed description about each subclassification.
CrDDS is one which delivers the drug at a predetermined rate, for locally or systematically, for a prolong period of time.
These systems are capable of controlling the rate of drug delivery, sustaining the duration of therapeutic efficacy, and/or targeting the delivery of drug to a tissue. Depending upon the technical sophistication, these rate-control drug delivery systems can be classified into three major categories: (i) pre-programmed drug delivery, (ii) activation-controlled drug delivery, and (iii) feedback-regulated drug delivery.
Upon completion of module on Google classroom you will able to
1. Understand concept of Google Classroom.
2. Create your own class using Google Classroom.
3. Invite students and teachers to join Google Class.
4. Add topics and course content in Classroom.
5. Create and conduct assignments for students.
6. Post announcements and notices.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
1. By
Kailas K Mali
Department of Pharmaceutics
YSPM’s Yashoda Technical Campus, Satara
E-mail: malikailas@gmail.com
Mobile No: 9552527353
04/21/18 1
2. Contents
Introduction
Classification of rate controlled DD Systems
Rate programmed Drug Delivery System
Activation Modulated Drug Delivery System
Feedback regulated Drug Delivery System
Effect of System Parameters on Controlled Drug Delivery
System
References
04/21/18 2
3. Introduction
Sustained release, sustained action, controlled release, extended
action, timed release dosage forms are the terms used to
identify drug delivery systems that are designed to achieve a
prolonged therapeutic effect by continuously releasing
medication over an extended period of time after the
administration of single dose.
The term “Controlled release” has become associated with those
systems from which therapeutic agents may be automatically
delivered at predefined rates over a long period of time.
But, there are some confusion in terminology between
“Controlled release” & “Sustained release”
04/21/18 3
4. Introduction
Sustained Release
The term sustained release has been constantly used to describe a
pharmaceutical dosage form formulated to retard the release of a
therapeutic agent such that its appearance in the systemic circulation
is delayed &/or prolonged & its plasma profile is sustained in duration.
Controlled Release
It implies a predictability & reproducibility in the drug release
kinetics, which means that the release of drug ingredient from a
controlled delivery system proceeds at a rate profile that is not only
predictable kinetically, but also reproducible from one unit to
another.
04/21/18 4
6. Advantages
Less fluctuation in drug blood levels.
Frequency reduction in dosing.
Improved patient convenience & compliance.
Increased safety margin of the high potency
drugs.
Reduction in total health care cost.
04/21/18 6
7. Disadvantages
Decreased systemic availability in comparison
to immediate release conventional dosage
forms.
Poor in vivo – in vitro correlation.
Possibility of dose dumping.
Retrieval of drug is difficult.
Higher cost of formulation.
04/21/18 7
8. Classification
Based on their technical sophistication :
Rate preprogrammed drug delivery system
Activation-modulated drug delivery system
Feedback-regulated drug delivery system
Site targeting drug delivery system
04/21/18 8
9. Rate preprogrammed DDS
In this group , the release of drug molecule from the
system has been preprogrammed at specific rate
profile.
Classification
1. Polymer membrane permeation-controlled drug
delivery system
2. Polymer matrix diffusion-controlled drug delivery
system
3. Microreservior partition-controlled drug delivery
system
04/21/18 9
10. Polymer membrane permeation-
controlled drug delivery
In this type, drug is totally or partially encapsulated within
drug reservoir.
Its drug release surface is covered by a rate-controlling
polymeric membrane having a specific permeability.
Drug reservoir may exist in solid, suspension or solution
form.
polymeric membrane can be fabricated from a nonporous
(homogeneous or heterogeneous) polymeric material or a
microporous (or semipermeable) membrane.
04/21/18 10
11. Polymer membrane permeation-
controlled drug delivery
The encapsulation of drug formulation inside the reservoir
compartment is accomplished by injection molding, spray
coating, capsulation, microencapsulation, or other
techniques.
Different shapes and sizes of drug delivery systems can be
fabricated.
04/21/18 11
14. Polymer membrane permeation-
controlled drug delivery
The rate of drug release defined by
Km/r & Ka/m= partition coefficient of the drug molecule from reservoir to rate
controlling membrane & from membrane to aq. Layer respectively.
Dd & Dm = diffusion coefficient of rate controlling membrane & aqueous
diffusion layer respectively.
hm & hd = thickness of rate controlling membrane & aqueous diffusion layer
respectively.
CR – drug conc. In reservoir compartment.
04/21/18 14
15. Polymer membrane permeation-
controlled drug delivery
Release of drug molecules is controlled by :
Partition coefficient of the drug molecule.
Diffusivity of the drug molecule.
The thickness of the rate controlling membrane.
04/21/18 15
16. Polymer membrane permeation-
controlled drug delivery
Ex. Progestasert IUD
The drug reservoir is a
suspension of progesterone &
barium sulphate in silicone
medical fluid & is encapsulated
in the vertical limb of a T-
shaped device walled by a non-
porous membrane of ethylene-
vinyl acetate co-polymer.
It is designed to deliver natural
progesterone continuously in
uterine cavity at a daily dosage
rate of at least 65 μg/day to
achieve contraception for 1 year.
04/21/18 16
17. Polymer membrane permeation- controlled
drug delivery
Ex. Transderm-Nitro
It is designed for application on to intact skin for 24 hrs to provide a
continuous transdermal infusion of nitroglycerin at dosage rate of 0.5
mg/cm2
/day for the treatment of angina pectoris
04/21/18 17
18. Polymer matrix diffusion- controlled
drug delivery
In this type, drug reservoir is prepared by homogeneously
dispersing drug particle in rate controlling polymer matrix
from either a lipophilic or a hydrophilic polymer.
The drug dispersion in the polymer matrix is
accomplished by either,
1. blending therapeutic dose of drug with polymer or highly
viscous base polymer, followed by cross linking of polymer
chains.
2. mixing drug solid with rubbery polymer at elevated temp.
04/21/18 18
19. Polymer matrix diffusion- controlled
drug delivery
The resultant drug-polymer dispersion is then molded or
extruded to form a drug delivery device of various shapes
and sizes designed for specific application.
It can also be fabricated by dissolving the drug and the
polymer in a common solvent, followed by solvent
evaporation at an elevated temperature and/or under a
vacuum.
Release of drug molecule is controlled by
Loading dose
Polymer solubility of drug
Drug diffusivity in polymer matrix.
04/21/18 19
22. Polymer matrix diffusion- controlled
drug delivery
The rate of the drug release from this system,
Where,
Q/t1/2
- rate of release of drug
A – initial drug loading dose in the polymer matrix
CR – drug solubility in polymer
Dp – diffusivity of drug in polymer matrix
04/21/18 22
23. Polymer matrix diffusion- controlled
drug delivery
Ex. Nitro-Dur
Nitro-Dur is a transdermal system contains nitroglycerin in acrylic-
based polymer adhesives with a resinous cross-linking agent to
provide a continuous source of active ingredient for 24h.
04/21/18 23
24. Polymer matrix diffusion- controlled
drug delivery
Ex. Nitro-Dur
The Compudose subdermal implant is fabricated by dispersing
micronized estradiol crystals in a viscous silicone elastomer and then
coating the estradiol-dispersing polymer around a rigid (drug-free)
silicone rod by extrusion to form a cylindrical implant.
This subdermal implant is developed for subcutaneous implantation
in steers for growth promotion and to release a controlled dose of
estradiol for as long as 200 or 400 days.
04/21/18 24
25. Microreservior partition- controlled
drug delivery system
In this type, drug reservoir is fabricated by micro
dispersion of an aqueous Suspension of drug in
biocompatible polymer to form homogeneous dispersion.
Depending upon the physicochemical properties of drugs
& desired rate of drug release, the device can be further
coated with a layer of biocompatible polymer to modify
the mechanism & the rate of drug release.
04/21/18 25
26. Microreservior partition- controlled
drug delivery system
The rate of drug release is defined by
Where,
n = the ratio of drug conc. At the inner edge of the interfacial barrier over the
drug solubility in the polymer matrix.
m = a/b, a – ratio of drug conc. In the bulk of elution solution over drug
solubility in the same medium.
b – ratio of drug conc. At the outer edge of the polymer coating membrane
over drug solubility in the same polymer.
Sl & Sp = solubilities of the drug in the liquid compartments & in the polymer
matrix, respectively.
04/21/18 26
27. Microreservior partition- controlled
drug delivery system
The rate of drug release is defined by
Where,
Kl, Km & Kp = partition coefficient for the interfacial partitioning of the drug
from the liquid compartment to the polymer matrix, from the polymer matrix
to the polymer-coating membrane & from the polymer coating membrane to
the elution solution respectively.
Dl, Dp & Dd = diffusivities of the drug in the lipid layer surrounding the drug
particle, the polymer coating membrane enveloping the polymer matrix, & the
hydrodynamic diffusion layer surrounding the polymer coating membrane
with the thickness hl, hp & hd.
04/21/18 27
28. Microreservior partition- controlled
drug delivery system
Release of drug molecules from this type of system can
follow either a dissolution or a matrix diffusion controlled
process depending upon the relative magnitude of Sl & Sp.
Release of drug molecule is controlled by,
Partition coefficient
Diffusivity of drug
Solubility of drug
04/21/18 28
29. Microreservior partition- controlled
drug delivery system
Ex. Syncro-Mate – C
It is fabricated by dispersing the drug reservoir, which is a
suspension of norgestomet in an aqueous solution of PEG
400, in a viscous mixture of silicone elastomer. It is
subdermal implat releases drug for 18 days
04/21/18 29
30. Microreservior partition- controlled
drug delivery system
Ex. Nitrodisc
Resiorvior is formed by first preparing a suspension of nitroglycerin and lactose
triturate in an aqueous solution of 40% polyethylene glycol 400 and dispersing it
homogeneously with isopropyl palmitate, as dispersing agent, in a mixture of viscous
silicone elastomer by high-energy mixing and then cross-linking the polymer chains by
catalyst.
The resultant drug-polymer dispersion is then molded to form a solid medicated disk in
situ on a drug-impermeable metallic plastic laminate, with surrounding adhesive rim, by
injection molding under instantaneous heating. It is engineered to provide a
transdermal administration of nitroglycerin at a daily dosage of 0.5 mg/cm2 for once-a
day medication of angina pectoris.
04/21/18 30
31. Activation modulated drug delivery systems
In this group of controlled release drug delivery system,
the release of drug molecules from the delivery system is
activated by some physical, chemical, or biochemical
process and/or by energy supplied externally.
04/21/18 31
32. Activation modulated drug delivery systems
Based on nature of the process or type of energy used
they can be classified into
1. Physical means
a. Osmotic pressure-activated DDS
b. Hydrodynamic pressure-activated DDS
c. Vapor pressure-activated DDS
d. Mechanically activated DDS
e. Magnetically activated DDS
f. Sonophoresis activated DDS
g. Iontophoresis activated DDS
h. Hydration-activated DDS
04/21/18 32
33. Activation modulated drug delivery systems
Based on nature of the process or type of energy used
they can be classified into
2. Chemical means
a. pH- activated DDS
b. Ion- activated DDS
c. Hydrolysis- activated DDS
3. Biochemical means
a. Enzyme- activated DDS
b. Biochemical- activated DDS
04/21/18 33
34. Osmotic pressure- activated drug delivery
systems
In this type, drug reservoir can be either solution or solid
formulation contained within semi permeable housing
with controlled water permeability.
The drug is activated to release in solution form at a
constant rate through a special delivery orifice.
The rate of drug release is modulated by controlling the
gradient of osmotic pressure.
04/21/18 34
35. Osmotic pressure- activated drug delivery
systems
For the drug delivery system containing a solution
formulation, the intrinsic rate of drug release is defined
by,
For the drug delivery system containing a solid
formulation, the intrinsic rate of drug release is defined
by,
04/21/18 35
36. Osmotic pressure- activated drug delivery
systems
Rate controlling factors :
Water permeability of the semi permeable membrane.
Effective surface area of the semi permeable membrane.
Osmotic pressure difference across the semi permeable
membrane.
04/21/18 36
37. Osmotic pressure- activated drug delivery
systems
Ex. Alzet Osmotic pump
In the Alzet osmotic pump the
drug reservoir, which is normally
a solution formulation, is
contained within a collapsible,
impermeable polyester bag
whose external surface is coated
with a layer of osmotically active
salt, such as sodium chloride.
This reservoir compartment is
then completely sealed inside a
rigid housing walled with a
semipermeable membrane.
drug can be delivered at a
constant rate for a period of 1-4
weeks.
04/21/18 37
38. Osmotic pressure- activated drug delivery
systems
Ex. Acutrim Tablet
An oral rate-controlled drug delivery device, is a solid tablet of water-
soluble and osmotically active phenylpropanolamine (PPA) HCl enclosed
within a semipermeable membrane made from cellulose triacetate.
The surface of the semipermeable membrane is further coated with a thin
layer of PPA dose for immediate release. In the gastrointestinal tract the
gastrointestional fluid dissolves the immediately releasable PPA layer,
which provides an initial dose of PPA.
It is designed to provide a controlled delivery of PPA over a duration of 16
hr for appetite suppression in a weight control program
04/21/18 38
39. Hydrodynamic pressure- activated drug delivery
systems
A hydrodynamic pressure-activated drug delivery system
can be fabricated by enclosing a collapsible, impermeable
container, which contains a liquid drug formulation to
form a drug reservoir compartment, inside a rigid shape-
retaining housing.
A composite laminate of an absorbent layer and a
swellable, hydrophilic polymer layer is sandwiched
between the drug reservoir compartment and the housing.
In the GIT the laminate absorbs the gastrointestinal fluid
through the annular openings at the lower end of the
housing and becomes increasingly swollen, which
generates hydrodynamic pressure in the system..
04/21/18 39
40. Hydrodynamic pressure- activated drug delivery
systems
Rate of drug release is defined by,
Where,
Pf = fluid permeability
Am = effective Surface area
hm = thickness of wall with anular opening
(θs - θe) = differential hydrodynamic pressure
between the drug delivery system & the environment.
04/21/18 40
41. Hydrodynamic pressure- activated drug delivery
systems
Rate controlling factors
Fluid permeability
Effective surface area of the wall with the annular opening.
Hydrodynamic pressure gradient.
04/21/18 41
42. Hydrodynamic pressure- activated drug delivery
systems
Cross-sectional view of a hydrodynamic pressure-activated
drug delivery system showing various structural
components.
04/21/18 42
43. Vapor pressure- activated drug delivery systems
In this type of drug delivery system the drug reservoir,
which also exists as a solution formulation, is contained
inside the infusion compartment. It is physically separated
from the pumping compartment by a freely movable
partition .
04/21/18 43
44. Vapor pressure- activated drug delivery systems
The pumping compartment contains a fluorocarbon fluid
that vaporizes at body temperature at the implantation
site and creates a vapor pressure.
Under the vapor pressure created the partition moves
upward.
This forces the drug solution in the infusion compartment
to be delivered through a series of flow regulator and
delivery cannula into the blood circulation at a constant
flow rate.
04/21/18 44
45. Vapor pressure- activated drug delivery systems
The rate of drug release is defined by,
Where-
Q/t - rate of drug release
d – inner diameter of cannula
l – length of cannula
(Ps -Pe)- the difference between the vapor pressure in the
vapor chamber & pressure at the implantation site.
µ − viscosity of the drug solution.
04/21/18 45
46. Vapor pressure- activated drug delivery systems
Rate controlling factors :
Differential vapor pressure
Formulation viscosity
Size of the delivery cannula
Ex. An implantable infusion pump for the constant
infusion of heparin for anti-coagulant therapy, insulin in
diabetic treatment & morphine for patient suffering from
the intensive pain of terminal cancer.
04/21/18 46
47. Mechanically- activated drug delivery systems
In this type, drug reservoir is in solution form retained in a
container equipped with mechanically activated pumping
system.
A measured dose of the drug formulation is reproducible
delivered in to a body cavity, for ex. The nose through the
spray head upon manual activation of the drug delivery
pumping system
04/21/18 47
48. Mechanically- activated drug delivery systems
The volume of solution delivered is controllable, as small
as 10-100 µl & is independent of the force & duration of the
activation applied as well as the solution volume in the
container.
04/21/18 48
49. Magnetically- activated drug delivery systems
In this type, drug reservoir is a dispersion of peptide or
protein powders in polymer matrix from which
macromolecular drug can be delivered only at a relatively
slow rate.
This low rate of delivery can be improved by incorporating
electromagnetically triggered vibration mechanism into
polymeric device combined with a hemispherical design.
Device is fabricated by positioning a tiny magnet ring in
core of hemispherical drug dispersing polymer matrix.
04/21/18 49
50. Magnetically- activated drug delivery systems
Device is fabricated by positioning a tiny magnet ring in
core of hemispherical drug dispersing polymer matrix.
The external surface is coated with drug impermeable
polymer (ethylene vinyl acetate or silicon elastomer)
except one cavity at the centre of the flat surface.
This delivery device used to deliver protein drugs such as
bovine serum albumin, at a low basal rate, by a simple
diffusion process under non triggering condition.
As the magnet is activated to vibrate by external
electromagnetic field, drug molecules are delivered at
much higher rate.
04/21/18 50
52. Sonophoresis- activated drug delivery systems
Also called as Phonophoresis.
This type of system utilizes ultrasonic energy to activate or
trigger the delivery of drug from polymeric drug delivery
device.
System can be fabricated from nondegradable polymer
(ethylene vinyl acetate) or bioerodiable polymer
(poly[bis(p-carboxyphenoxy) alkane anhydride]
The potential application of sonophoresis to regulate the
delivery of drugs was recently reviewed.
04/21/18 52
54. Iontophoresis- activated drug delivery systems
This type of system uses electrical current to activate & to
modulate the diffusion of charged drug across biological
membrane.
Iontophoresis – facilitated skin permeation rate of charged
molecule (i) consist of 3 components & is expressed by,
Ji
isp
= Jp
+ Je
+Jc
Where,
Jp–
passive skin permeation flux
Je
– electrical current driven permeation flux
Jc
= convective flow driven skin permeation flux04/21/18 54
55. Iontophoresis- activated drug delivery systems
This system to
facilitate the
percutaneous
penetration of
anti-
inflammatory
drugs such as
dexamethasone
sodium
phosphate to
surface tissue.
04/21/18 55
56. Hydration- activated drug delivery systems
In this system, the drug reservoir is homogeneously
dispersed in a swellable polymer matrix fabricated from a
hydrophilic polymer (ethylene glycomethacrylate).
The release of drug is controlled by the rate of swelling of
polymer matrix.
04/21/18 56
57. pH- activated drug delivery systems
This type of chemically activated system permits targeting
the delivery of drug only in the region with selected pH
range.
It fabricated by coating the drug-containing core with a
pH – sensitive polymer combination.
For instances, a gastric fluid labile drug is protected by
encapsulating it inside a polymer membrane that resist
the degradative action of gastric pH.
04/21/18 57
59. pH- activated drug delivery systems
In the stomach, coating membrane resists the action of
gastric fluid (pH<3) & the drug molecule thus protected
from acid degradation.
After gastric emptying the DDS travels to the small
intestine & intestinal fluid (pH>7.5) activates the erosion
of the intestinal fluid soluble polymer from the coating
membrane.
This leaves a micro porous membrane constructed from
the intestinal fluid insoluble polymer, which controls the
release of drug from the core tablet.
The drug solute is thus delivered at a controlled manner
in the intestine by a combination of drug dissolution &
pore-channel diffusion.
04/21/18 59
60. Ion- activated drug delivery systems
An ionic or a charged drug can be delivered by this
method & this system are prepared by first complexing an
ionic drug with an ion-exchange resin containing a
suitable counter ion.
Ex. By forming a complex between a cationic drug with a
resin having a So3
-
group or between an anionic drug with a
resin having a N(CH3)3 group.
The granules of drug-resin complex are first treated with
an impregnating agent & then coated with a water-
insoluble but water-permeable polymeric membrane.
04/21/18 60
62. Ion- activated drug delivery systems
This membrane serves as a rate-controlling barrier to
modulate the influx of ions as well as the release of drug
from the system.
In an electrolyte medium, such as gastric fluid ions diffuse
into the system react with drug resin complex & trigger
the release of ionic drug.
Since the GI fluid regularly maintains a relatively constant
level of ions, theoretically the delivery of drug from this
ion activated oral drug delivery system can be maintained
at a relatively constant rate.
04/21/18 62
63. Hydrolysis- activated drug delivery systems
This type of system depends on the hydrolysis process to
activate the release of drug.
Drug reservoir is either encapsulated in microcapsules or
homogeneously dispersed in microspheres or nano
particles for injection.
It can also be fabricated as an implantable device.
All these systems prepared from bioerodible or
biodegradable polymers (polyanhydride, polyorthoesters).
It is activated by hydrolysis-induced degradation of
polymer chain & is controlled by rate of polymer
degradation.04/21/18 63
64. Hydrolysis- activated drug delivery systems
Ex. LHRH
Releasing biodegradable subdermal implant, which is
designed to deliver goserline, a synthetic LHRH analog for
once a month treatment of prostate carcinoma.
04/21/18 64
65. Enzyme - activated drug delivery systems
This type of biochemical system depends on the
enzymatic process to activate the release of drug.
Drug reservoir is either physically entrapped in
microspheres or chemically bound to polymer chains from
biopolymers (albumins or polypeptides).
The release of drug is activated by enzymatic hydrolysis of
biopolymers (albumins or polypeptides) by specific
enzyme in target tissue.
04/21/18 65
66. Feedback - activated drug delivery systems
In this group the release of drug molecules from the
delivery system is activated by a triggering agent.
Rate of drug release is controlled by concentration of
triggering agent.
They are further classified as
Bioerosion-regulated drug delivery system
Bioresponsive drug delivery system
Self-regulating drug delivery system
04/21/18 66
67. Feedback - activated drug delivery systems
Bioerosion – regulated DDS
The system consisted of drug-dispersed bioerodible matrix
fabricated from poly (vinyl methyl ether) ester which is
coated with layer of immobilized urease.
04/21/18 67
•In a solution with near
neutral pH, the polymer
only erodes very
slowly.
•In presence of urea,
urease metabolizes
urea to form ammonia.
This causes increase
in pH & rapid
degradation of polymer
with release of drug
molecule.
68. Feedback - activated drug delivery systems
Bioresponsive – regulated DDS
Drug reservoir is contained in device enclosed by
bioresponsive polymeric membrane whose drug
permeability is controlled by concentration of biochemical
agent.
Glucose-triggered insulin delivery system in which the
insulin reservoir is encapsulated within a hydrogel
membrane having pendant NR2 groups . In alkaline
solution the — NR2 groups are neutral and the membrane
is unswollen and impermeable to insulin. As glucose, a
triggering agent, penetrates into the membrane, it is
oxidized enzymatically by the glucose oxidase entrapped
in the membrane.
04/21/18 68
69. Feedback - activated drug delivery systems
Bioresponsive – regulated DDS
Ex. – glucose-triggered insulin drug delivery system.
04/21/18 69
70. Feedback - activated drug delivery systems
Self – regulated DDS
This type of system depends on a reversible & competitive
binding mechanism to activate and to regulate the release
of drug.
Drug reservoir is drug complex encapsulated within a
semi permeable polymeric membrane.
The release of drug from the delivery system is activated
by the membrane permeation of biochemical agent from
the tissue in which the system is located.
04/21/18 70
71. Feedback - activated drug delivery systems
Self – regulated DDS
Ex. In the complex of glycosylated insulin concanavalin A,
which is encapsulated inside a polymer membrane.
Glucose penetrates into the system & it activates the
release of glycosylated insulin from the complex for
controlled delivery out of system.
04/21/18 71
72. Effect of system parameters
Polymer solubility
Solution solubility
Partition coefficient
Polymer diffusivity
Solution diffusivity
Thickness of polymer diffusional path
Thickness of hydrodynamic diffusion layer
Drug loading dose
Surface area
04/21/18 72
73. Polymer diffusivity (DP)
The diffusion of small molecules in a polymer structure is
a energy activated process in which the diffusant
molecules move to a successive series of equilibrium
positions when a sufficient amount of energy of activation
for diffusion Ed, has been acquired by the diffusant & it’s
surrounding polymer matrix.
This energy- activated diffusion process is frequently
described by the following Arrhenius relationship :
Dp = D0 e-(Ed/RT)
04/21/18 73
74. Polymer diffusivity (DP)
The bulkier the functional group attached to polymer
chain lower the polymer diffusivity.
Magnitude of polymer diffusivity is dependant upon type
of functional group and type of stereo chemical position in
diffusant molecule.
Polymer diffusivity also depends on
1) Effect of cross linking
2) Effect of crystallinity
3) Effect of fillers
04/21/18 74
75. Solution diffusivity (DS)
The diffusion of solute molecules in solution medium is a
result of the random motion of molecules.
Under concentration gradient molecule diffuse
spontaneously from higher concentration to lower
concentration.
The diffusivity of the solute molecules in the aqueous
solution whose molar volume is equal to or greater than
the molar volume of water molecules is inversely
proportional to the cube root of their volume.
04/21/18 75
76. Solution diffusivity (DS)
When solution diffusivity are compared on bases of
molecular volume, alkanes are most rapidly diffusing
chemicals.
The relative rates of diffusion of various chemical classes
are as follows :
alkane > alcohol > amides > acids > amino acids >
dicarboxylic acid
Diffusivity of solute molecule in aqueous solution usually
decreases as its concentration increases.
04/21/18 76
77. Thickness of polymer diffusional path (hP)
Control release of drug species from both polymer
membrane & polymer matrix controlled drug delivery
system is governed by,
1) The solute diffusion coefficient in the membrane lipid.
2) The thickness of the membrane.
04/21/18 77
78. Thickness of polymer diffusional path (hP)
hp value for polymer membrane controlled reservoir
devices, which are fabricated from non biodegradable and
non swollen polymer, the value is defined by polymer wall
with constant thickness that is invariable with time span.
In polymer matrix controlled reservoir devices, which are
fabricated from non biodegradable polymers, the
thickness of diffusional path is defined as drug depletion
zone progressively in proportion to the square root of
time.
04/21/18 78
79. Thickness of polymer diffusional path (hP)
The rate of growth in the hpvalue can be defined
mathematically by :
Where,
Cp= solubility of drug in the polymer phase
Dp= diffusivity of drug in the polymer matrix
04/21/18 79
2/1
2/1
2/
2
−
=
p
ppp
CA
DC
t
h
80. Thickness of hydrodynamic diffusion layer (hd)
The hydrodynamic diffusion layer has a rate limiting role
on controlled release dosage form.
Magnitude of drug release value decreases as the thickness
of hydrodynamic diffusion layer is increased.
04/21/18 80
81. Polymer Solubility
Drug particles are not released until they dissociate from
their crystal lattice structure, dissolve or partition into
surrounding polymer.
Solubility of drug in polymer membrane or matrix plays
important role in it’s release from a polymeric device.
For a drug to release at an appropriate rate the drug
should have adequate polymer solubility.
Rate of drug release is directly proportional to magnitude
of polymer solubility.
04/21/18 81
82. Solution solubility
Aqueous solubility varies from one drug to another.
Difference in aqueous solubility is depend on the difference in
their chemical structure, types & physicochemical nature of
functional groups & the variations in their stereo chemical
configurations.
By using a water – miscible cosolvent as a solubilizer & addition
of the cosolvent into the elution solution to increase the
solution solubility of drugs.
Solubilization of poorly soluble drug in aqueous solution can be
accomplished by using multiple co-solvent system.
Drug release increases with increase in Solution solubility of
drug.04/21/18 82
83. Partition coefficient
Partition co-efficient K of a drug for it’s interfacial
partitioning from the surface of a drug delivery device
towards an elution medium as given :
K = Cs/Cp
Where,
Cs= conc. Of drug at the solution/polymer interface
Cp= solubility of drug in the polymer phase.
04/21/18 83
84. Partition coefficient
Ratio of drug solubility in the elution solution Csover its
solubility in polymer composition Cp of device.
Any variation in either Cs or Cp result in increase or
decrease in magnitude of ‘K’ value.
Rate of drug release increase with increase in partition
coefficient.
04/21/18 84
85. Drug loading dose
In preparation of the device varying loading doses of drugs
are incorporated, as required for different length of
treatment.
Variation in the loading doses results only in the change
in duration of action with constant drug release profile.
04/21/18 85
86. Surface area
Both the in-vivo & in-vitro rates of drug release dependant
on the surface area of the drug delivery device.
Greater the surface area greater will be the rate of drug
release.
04/21/18 86
The controlled release of drug molecules from a membrane permeation-controlled reservoir-type drug delivery device of various shapes in which drug is contained in a reservoir compartment enclosed by a polymer membrane. CR, drug concentration in the drug reservoir compartment; Cp, the solubility of drug in the polymer phase; Cm, the concentration of drug at the polymer/solution interface; Cs, the concentration of drug at the
solution/polymer interface; Cb, the concentration of drug in the bulk of elution solution; hm, thickness of the membrane wall; and hd, thickness of the hydrodynamic diffusion layer.
Transderm-Nitro is a transdermal therapeutic system in which the drug reservoir, a dispersion of nitroglycerin-lactose triturate in the silicone medical fluid, is encapsulated in a thin ellipsoidal patch. The transdermal patch is constructed from a drug impermeable metallic plastic laminate as the backing membrane and a constant surface of rate-controlling microporous membrane of ethylene-vinyl acetate copolymer as the drug-releasing surface. This device is fabricated by an injection molding process. Additionally, a thin layer of pressure-sensitive silicone adhesive
polymer is coated on the surface of the rate-controlling membrane to achieve an intimate contact of the drug release surface with the skin. It is engineered to deliver nitroglycerin at dosage rate of 0.5 mg/cm2/day for transdermal absorption to provide daily relief of anginal attacks.
The controlled release of drug molecules from a polymer matrix diffusion-controlled dispersion-type drug delivery device in which solid drug is homogeneously dispersed in the polymer matrix. A, the initial amount of drug solids impregnated in a unit volume of polymer matrix; CR, the reservoir concentration or saturated concentration of drug in the polymer phase; Dp, the diffusivity of drug in the polymer matrix; hp and hd, the thicknesses of the drug depletion zone in the matrix and of the hydrodynamic diffusion layer on the immediate surface of the device, respectively; and d(hp), the differential thickness of the depletion zone formed following the release of more drug solids.
Nitro-Dur is a transdermal drug delivery (TDD) system fabricated by first heating an aqueous solution of water-soluble polymer, glycerol, and polyvinyl alcohol. The temperature of the solution is then gradually lowered and nitroglycerin and lactose triturate are dispersed just above the congealing temperature of the solution. The mixture is solidified in a mold at or below room temperature and then sliced to form a medicated polymer disk. After assembly onto a drug-impermeable metallic plastic laminate, a patch-type TDD system is produced with an adhesive rim surrounding the medicated disk. It is designed for application onto intact skin for 24 hr to provide a continuous transdermal infusion of itroglycerin at a dosage rate of 0.5 mg/cm2/day for the treatment of angina pectoris.
The subdermal Syncro-Mate-C implant is fabricated by dispersing the drug reservoir, which is a suspension of norgestomet in an aqueous solution of PEG 400, in a viscous mixture of silicone elastomers by high-energy dispersion. After the addition of catalyst the suspension is delivered into silicone medical-grade tubing, which serves as the mold as well as the coating membrane, and then polymerized in situ. The polymerized drug-polymer composition is then cut into a cylindrical drug delivery device with open ends. This tiny cylindrical implant is designed to be inserted into the subcutaneous tissue of the livestock&apos;s ear flap and to release norgestomet for up to 20 days for the control and synchronization of estrus and ovulation as well as for up to 160 days for growth promotion.
first preparing a suspension of nitroglycerin and lactose triturate in an aqueous solution of 40% polyethylene glycol 400 and dispersing it homogeneously with isopropyl palmitate, as dispersing agent, in a mixture of viscous silicone elastomer by high-energy mixing and then cross-linking the polymer chains by catalyst (26). The resultant drug-polymer dispersion is then molded to form a solid medicated disk in situ on a drug-impermeable metallic plastic laminate, with surrounding adhesive rim, by injection molding under instantaneous heating. It is engineered to provide a transdermal administration of nitroglycerin at a daily dosage of 0.5 mg/cm2 for once-a day medication of angina pectoris.